The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA ...
Moderna on Friday said the Food and Drug Administration won't meet its May 12 target action date for a decision on the company's proposed vaccine for respiratory syncytial virus, or RSV, but ...
Moderna reported better-than-expected 1Q24 revenue of $167 million and its pipeline looks promising. Read my earnings ...
The FDA has not informed Moderna of any issues related to vaccine safety, efficacy, or quality that would prevent the approval of mRNA-1345. Moderna remains on track for mRNA-1345 to be reviewed ...
Moderna (NASDAQ:MRNA) shares are down just over 1% in early Friday trading after the company said the FDA has informed it that it will not be able to meet the May 12 PDUFA for their RSV vaccine ...
Moderna (NASDAQ:MRNA) announced Friday that the U.S. Food and Drug Administration (FDA) has pushed back its timeline to complete the review of its marketing application for mRNA-1345, a messenger ...